Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
456 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT01916317 | Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer | active not recruiting | Phase 3 | 1,600 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03168880 |
| A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer(TNBC) |
| active not recruiting |
| Phase 3 |
| 720 |
| Tata Memorial HospitalOTHER_GOV |
| 1 |
| Apr 9, 2025 |
| clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 3 | 652 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 21, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT02867865 | Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers(POLCAGB) | active not recruiting | Phase 2 / Phase 3 | 124 | Tata Memorial HospitalOTHER_GOV | 1 | Mar 13, 2025 | clinicaltrials |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | completed | Phase 3 | 369 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT00353496 | Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours(CLARINET) | completed | Phase 3 | 264 | IpsenINDUSTRY | 15 | Mar 5, 2025 | clinicaltrials |
| NCT06737822 | Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:(SurVIC) | recruiting | Phase 3 | 346 | All India Institute of Medical Sciences, JodhpurOTHER_GOV | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05732805 | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma(OCTAVA) | active not recruiting | Phase 3 | 270 | BiocadINDUSTRY | 3 | Feb 27, 2025 | clinicaltrials |
| NCT03936933 | Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer | terminated | Phase 3 | 6 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT02951325 | Bladder Cancer Adjuvant Radiotherapy Trial(BART) | active not recruiting | Phase 3 | 153 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT01828099 | LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | completed | Phase 3 | 376 | Novartis PharmaceuticalsINDUSTRY | 29 | Jan 16, 2025 | clinicaltrials |
| NCT03769506 | ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | active not recruiting | Phase 3 | 135 | Rakuten Medical, Inc.INDUSTRY | 4 | Jan 16, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT02085408 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 727 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 13, 2024 | clinicaltrials |
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer(INTERLACE) | active not recruiting | Phase 3 | 500 | University College, LondonOTHER | 5 | Dec 5, 2024 | clinicaltrials |
| NCT01554397 | Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | completed | Phase 2 / Phase 3 | 101 | University of California, San DiegoOTHER | 6 | Nov 29, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
| NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)(HL-Russia-1) | recruiting | Phase 3 | 300 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaOTHER | 2 | Sep 27, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT05833815 | Addition of Everolimus to Standard of Care in Carcinoma Gallbladder | unknown | Phase 2 / Phase 3 | 56 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05865548 | Addition of Aspirin to Standard of Care in Oral Cancer | completed | Phase 2 / Phase 3 | 60 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)(CALLA) | completed | Phase 3 | 770 | AstraZenecaINDUSTRY | 15 | Jul 26, 2024 | clinicaltrials |
| NCT05283837 | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) | completed | Phase 3 | 268 | Zydus Lifesciences LimitedINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04642469 | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.(MERMAID-2) | completed | Phase 3 | 30 | AstraZenecaINDUSTRY | 25 | Jun 25, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT02603432 | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) | completed | Phase 3 | 700 | PfizerINDUSTRY | 29 | Mar 27, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(MONALEESA-7) | completed | Phase 3 | 672 | Novartis PharmaceuticalsINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT03337724 | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer(IPATunity130) | completed | Phase 3 | 579 | Hoffmann-La RocheINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT00565708 | Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers(ASCOLT) | unknown | Phase 3 | 1,587 | National Cancer Centre, SingaporeOTHER | 10 | Feb 2, 2024 | clinicaltrials |
| NCT01763645 | A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 3 | 353 | BiocadINDUSTRY | 4 | Jan 11, 2024 | clinicaltrials |
| NCT00957086 | Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer | unknown | Phase 3 | 710 | National Cancer Centre, SingaporeOTHER | 13 | Jan 9, 2024 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT05144867 | Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis(SRSvsWBRT) | unknown | Phase 3 | 98 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03761225 | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | completed | Phase 3 | 714 | AB ScienceINDUSTRY | 6 | Sep 29, 2023 | clinicaltrials |
| NCT04914195 | Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer | completed | Phase 3 | 155 | Bharat Serums and Vaccines LimitedINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT01424566 | A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer | completed | Phase 3 | 406 | Jazz PharmaceuticalsINDUSTRY | 13 | Apr 12, 2023 | clinicaltrials |
| NCT01721876 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | completed | Phase 3 | 666 | Boehringer IngelheimINDUSTRY | 25 | Feb 8, 2023 | clinicaltrials |
| NCT03433313 | Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | completed | Phase 3 | 807 | EirGenix, Inc.INDUSTRY | 11 | Jan 20, 2023 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials